Target intelligence / Profile preview

Vacuolar protein sorting-associated protein 72–Histone H2A.Z protein–protein interface (VPS72–H2A.Z interface)

Target
VPS72–H2A.Z interface
Molecular classification
Protein-protein interface, Histone chaperone, Chromatin remodeling complex subunit
01

Overview

The Vacuolar protein sorting-associated protein 72 (VPS72), also known as YL1, is a dedicated histone chaperone responsible for the site-specific deposition of the histone variant H2A.Z into chromatin (UniProt Q15906). This protein-protein interface involves the binding of the VPS72 C-terminal domain to the H2A.Z-H2B heterodimer, facilitating its incorporation into nucleosomes via the SRCAP and p400/TIP60 remodeling complexes (Liang et al., 2016, Nature). The exchange of canonical H2A for H2A.Z is a fundamental epigenetic mechanism that regulates promoter accessibility, transcriptional activation, and the DNA damage response (Latrick et al., 2016, Nat Struct Mol Biol). In various cancers, including breast, prostate, and melanoma, the VPS72–H2A.Z axis is frequently upregulated, driving oncogenic gene expression and contributing to therapeutic resistance (Vardabasso et al., 2015, Nat Commun). Targeting this specific interface offers a strategy to selectively inhibit H2A.Z-mediated pathways without affecting global histone dynamics. While no clinical drugs currently target this interface, experimental approaches using peptidomimetics and small-molecule screens are being explored to disrupt this interaction for cancer therapy.

Other names
YL1–H2A.Z interfaceVPS72–H2AFZ interfaceYL1–H2AFZ protein-protein interactionVPS72–H2A.Z-H2B complex interface
02

Mechanism of action

Inhibition of H2A.Z deposition into chromatin by competitively disrupting the chaperone-histone binding interface

03

Biological functions

Histone exchangeChromatin remodelingTranscriptional regulationDNA repairCell cycle regulationGenome stability maintenance
04

Disease associations

CancerProstate cancerBreast cancerMelanomaLeukemiaFloating-Harbor syndrome (indirectly via SRCAP)
05

Safety considerations

Global epigenetic dysregulationImpairment of DNA damage repair mechanismsPotential toxicity to rapidly dividing healthy cellsOff-target transcriptional effects
06

Interacting drugs

Experimental peptide inhibitors (e.g., YL1-C derived peptides)

1 more in the full profile.

07

Biomarkers

H2A.Z chromatin occupancy levelsVPS72 (YL1) protein expressionH2A.Z/H2A ratio in nucleosomesSRCAP complex activity

Beyond the preview

Go deeper on Vacuolar protein sorting-associated protein 72–Histone H2A.Z protein–protein interface (VPS72–H2A.Z interface).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vacuolar protein sorting-associated protein 72–Histone H2A.Z protein–protein interface (VPS72–H2A.Z interface).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call